250 related articles for article (PubMed ID: 10563226)
1. The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
Hamel E
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S2-6. PubMed ID: 10563226
[TBL] [Abstract][Full Text] [Related]
2. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
3. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
4. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
5. New insights into the molecular actions of serotonergic antimigraine drugs.
Durham PL; Russo AF
Pharmacol Ther; 2002; 94(1-2):77-92. PubMed ID: 12191595
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology of migraine--new insights.
Hargreaves RJ; Shepheard SL
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S12-9. PubMed ID: 10563228
[TBL] [Abstract][Full Text] [Related]
7. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
8. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
Villalón CM; VanDenBrink AM
Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
[TBL] [Abstract][Full Text] [Related]
9. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
10. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.
Bouchelet I; Case B; Olivier A; Hamel E
Br J Pharmacol; 2000 Feb; 129(3):501-8. PubMed ID: 10711348
[TBL] [Abstract][Full Text] [Related]
11. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
12. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
13. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis.
Sakai Y; Dobson C; Diksic M; Aubé M; Hamel E
Neurology; 2008 Feb; 70(6):431-9. PubMed ID: 18250288
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
15. 5-HT(1)-like receptor agonists and the pathophysiology of migraine.
Saxena PR; Ferrari MD
Trends Pharmacol Sci; 1989 May; 10(5):200-4. PubMed ID: 12722735
[TBL] [Abstract][Full Text] [Related]
16. Neurogenic inflammation in the context of migraine.
Williamson DJ; Hargreaves RJ
Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
[TBL] [Abstract][Full Text] [Related]
17. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
18. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
19. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
Peroutka SJ
Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
[Next] [New Search]
